Skip to main content
. 2015 Mar 26;6(13):10978–10993. doi: 10.18632/oncotarget.3452

Table 3. Altered transcript expression in PTC samples as compared to benign counterparts from different donors.

Gene P-value (PTC vs benign) P-value with FDR (PTC vs benign) Fold change Total number of samples Number of samples with expression value > 50 (linear scale)
Without consideration of clinical aggressiveness
BCL2 5.86 × 10−11 3.51 × 10−10 −3.17 34 34
BMAL1 5.56 × 10−10 2.50 × 10−9 4.44 34 34
CHEK1 8.88 × 10−4 1.45 × 10−3 2.97 34 32
c-KIT 4.60 × 10−7 1.38 × 10−6 –10.80 34 32
c-MET 5.15 × 10−13 9.27 × 10−12 5.96 34 34
PPARγ 6.33 × 10−6 1.42 × 10−5 −3.96 34 31
TG 2.71 × 10−6 6.96 × 10−6 −3.85 34 34
TIMP1 1.02 × 10−11 9.18 × 10−11 6.27 34 34
VEGFR1 2.42 × 10−4 4.36 × 10−4 –2.18 34 34
ALDH1 3.97 × 10−8 6.75 × 10−7 –5.69 20 20
DIO2 2.51 × 10−3 5.34 × 10−3 –3.61 20 20
With consideration of clinical aggressiveness: more aggressive PTC (group II in Table 1)
AKT2 6.75 × 10−5 1.35 × 10−4 −2.01 32 32
BCL2 1.28 × 10−10 7.70 × 10−10 −3.24 32 32
BMAL1 1.74 × 10−9 7.82 × 10−9 4.05 32 32
CHEK1 1.30 × 10−3 1.79 × 10−3 3.01 32 30
CRY2 1.40 × 10−8 5.02 × 10−8 −2.02 32 32
c-KIT 3.22 × 10−7 9.65 × 10−7 −12.21 32 30
c-MET 2.48 × 10−12 4.47 × 10−11 5.99 32 32
PPARγ 1.61 × 10−6 3.61 × 10−6 −4.46 32 29
TG 1.14 × 10−6 2.92 × 10−6 −4.23 32 32
TIMP1 5.38 × 10−11 4.85 × 10−10 5.91 32 32
VEGFR1 7.51 × 10−5 1.35 × 10−4 −2.37 32 32
ALDH1 1.49 × 10−7 2.53 × 10−6 −5.64 19 19
DIO2 3.81 × 10−3 8.10 × 10−3 −3.65 19 19

The fold changes between the transcript expression levels in PTC and benign (B) samples were calculated as follows: Fc (fold change) PTC/B = 2(average log(PTC)-average log(B)) where PTC and B are normalized expression values obtained by NanoString analysis for the respective samples.